Pharma stock hits 20% upper circuit after its net profits grows by 186.2% YoYPharma stock hits 20% upper circuit after its net profits grows by 186.2% YoY

Introduction:

Leading pharma company reported a strong Q3 FY25 performance, with a 186.2% YoY increase in net profit, reaching ₹19.60 crore. Revenue from operations grew 23.3% YoY to ₹176.86 crore, showcasing robust growth and improved operational efficiency.

Also Read: Engineering stock jumps 5% after it receives 2 orders worth ₹8 Cr

Share price movement of Venus Remedies:

On February 5, 2025, Venus Remedies Ltd opened at ₹334.00, up 15.0% from its previous close of ₹290.50. The stock reached a high of ₹348.60 (20.00%) and a low of ₹329.00. By 10:16 AM, it traded at ₹348.60, a 20.00% increase, with a market cap of ₹465.97 crore.

Venus Remedies Reports Strong Q3 FY25:

Venus Remedies Ltd posted a net profit of ₹19.60 crore in Q3 FY25, marking a 186.2% year-on-year (YoY) increase from ₹6.85 crore in Q3 FY24. Sequentially, net profit surged 458.4% from ₹3.51 crore in Q2 FY25, highlighting strong financial performance.

Revenue from operations reached ₹176.86 crore, a 23.3% YoY rise from ₹143.42 crore in Q3 FY24. Compared to Q2 FY25, revenue increased 5.6% from ₹167.45 crore. Total income stood at ₹178.89 crore, up 22.7% YoY from ₹145.77 crore and 0.48% from ₹178.03 crore sequentially.

EBITDA surged 41.7% YoY to ₹20.39 crore from ₹14.39 crore, reflecting improved operational efficiency. On a quarter-on-quarter (QoQ) basis, EBITDA increased 31.6% from ₹15.49 crore. The company’s robust financials indicate strong growth momentum, driven by expanding operations and enhanced cost management.

Recent news on Venus Remedies:

As of January 20, 2025, Venus Remedies Ltd successfully renewed its European Good Manufacturing Practices (GMP) certification from Infarmed, Portugal’s national authority. This certification covers its manufacturing facility for key pharmaceutical products, ensuring continued delivery of world-class formulations to the European market.

Ace investor holding in Venus Remedies:

K. B. Shekar

K. B. Shekar holds a 1.97% stake in Venus Remedies Ltd, with 262,680 shares valued at ₹9.2 crore. His investment reflects confidence in the company’s growth prospects and performance in the pharmaceutical sector.

Stock performance of Venus Remedies for Period of 1 week, 6 months and 1 year:

Venus Remedies Ltd recorded a 0.36% increase in stock price over the past week. However, it experienced a 26.2% decline over six months and a 24.6% drop over the past year, reflecting challenges in long-term performance.

Also Read: Infra stock jumps 10% after its PAT increases by 45.3% YoY

Shareholding pattern of Venus Remedies:

All values in %	Dec 2024	Sep 2024	Jun 2024
Promoter	41.80%	41.80%	41.80%
FII	1.10%	1.20%	1.10%
DII	0%	0.20%	0.20%
Public	57.10%	56.90%	57.00%

About Venus Remedies:

Venus Remedies Ltd (NSE: VENUSREM) is a research-based pharmaceutical company established in 1989, specializing in injectables. It is a major manufacturer of meropenem antibiotics and offers a diverse range of products in various therapeutic areas, with over 1,040 marketing authorizations globally.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.